OurCongressPublic Data • Non-Partisan
Built to help voters quickly verify how officials vote — district first, party second. All information is sourced from official public records.
← Back to bills
HR. 1064 · 119th Congress

Stopping Overdoses of Fentanyl Analogues Act

In committee

This bill has not become law. Status shown reflects the latest official action.

See what this could mean for your district

Save your district in Account to view district-specific context for this bill.

Set my district

Bill details

Introduced: 2/6/2025
Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Bill ID: 119hr1064
Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Summary

Introduced in House

Stopping Overdoses of Fentanyl Analogues Act This bill permanently adds fentanyl-related substances to schedule I of the Controlled Substances Act. (A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.) Fentanyl-related substances are currently regulated under schedule I through a temporary order issued by the Drug Enforcement Administration. The temporary order expires March 31, 2025.

Source: BILLSUM · Summary date: 2/6/2025

District impact notes

1 notes
NEUTRAL
3/16/2026

The Stopping Overdoses of Fentanyl Analogues Act seeks to permanently classify fentanyl-related substances as schedule I controlled substances. • This policy could impact local law enforcement and public health efforts related to substance abuse. • Local healthcare providers may need to adjust their practices in response to changes in drug classification and availability. • There may be questions about how effectively the new regulations can be enforced and the resources required for compliance. AI-generated from official bill summary and plain-English note; verify with official text.

Related votes

Roll calls that reference this bill in official data.

0 roll calls
No related roll calls found yet for this bill.

Primary sources

Official links to verify details. (No interpretation.)

Summary source label: BILLSUM
Congress.gov bill →GovInfo bill text (BILLS) →GovInfo summaries (BILLSUM) →OurCongress methodology →
About this data
  • OurCongress is non-partisan by design. We do not add political interpretation or advocacy.
  • Bill data and official summaries come from GovInfo and Congress.gov. Some bills do not have published summaries yet.
  • District impact notes (when shown) are AI-generated from official bill metadata/summaries to improve readability. They are not official government language.
  • This page updates automatically via a daily ingestion pipeline.

About this data

Non-partisan by design
OurCongress provides plain-English context without endorsements, political interpretation, or advocacy.
Official sources
Data is sourced from official government records (e.g., Congress.gov, GovInfo, Clerk of the House, and the U.S. Senate).
AI-generated text
Some sections may be AI-generated from official summaries/metadata to help readability. AI output can be imperfect—verify with primary sources.
Last updated: 3/16/2026Source: BILLSUMBill: 119hr1064Learn more →